| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
DLin-MK-DMA is a cationic lipid that can be used in the construction of biological delivery vehicles. It does not have a biological target but is a formulation excipient. It is crucial for efficient gene delivery, improving cellular uptake and endosomal escape, thus enhancing therapeutic efficacy.
|
|---|---|
| ln Vitro |
In vitro, DLin-MK-DMA is used as a cationic lipid component in lipid nanoparticles for drug and gene delivery. It improves cellular uptake and endosomal escape. It is used to encapsulate nucleic acids (mRNA, siRNA) and small molecule drugs for delivery to cells.
|
| ln Vivo |
In vivo, DLin-MK-DMA is used in lipid nanoparticle formulations for drug delivery. It is a key component of lipid nanoparticles used in mRNA vaccines and gene therapies. It enhances the delivery of therapeutic payloads to target tissues.
|
| Enzyme Assay |
Cell-free assays for DLin-MK-DMA: lipid nanoparticle characterization includes particle size measurement by dynamic light scattering, zeta potential analysis, and encapsulation efficiency by HPLC or fluorescence. Lipid bilayer formation is assessed by surface pressure measurements. Endosomal escape is evaluated using fluorescence-based assays.
|
| Cell Assay |
Cellular assays for DLin-MK-DMA: cells are treated with DLin-MK-DMA-containing lipid nanoparticles at concentrations of 0.1-100 µM for 24-72 hours. Cellular uptake is assessed by fluorescence microscopy or flow cytometry. Gene delivery efficiency is measured by reporter gene expression (e.g., luciferase, GFP). Cell viability is measured by MTT assay. Cytotoxicity and inflammatory responses are evaluated.
|
| Animal Protocol |
In vivo animal studies for DLin-MK-DMA: pharmacokinetic and biodistribution studies of DLin-MK-DMA-based lipid nanoparticles are performed in rodents. Animals are administered the formulation intravenously or intramuscularly. Drug or nucleic acid concentrations in plasma and tissues are measured by HPLC, LC-MS/MS, or qPCR. Toxicity and tolerability are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of DLin-MK-DMA: as a cationic lipid (molecular weight 628.07), it is a component of lipid nanoparticles. Its pharmacokinetics depend on the formulation. It is metabolized and cleared from the body. Storage: at -20°C. Soluble in DMSO at 100 mg/mL.
|
| Toxicity/Toxicokinetics |
Toxicity of DLin-MK-DMA: comprehensive toxicity data are limited. As a cationic lipid, it may have dose-dependent cytotoxicity and inflammatory effects. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
DLin-MK-DMA is a research lipid used in nanomedicine and drug delivery research. It is available as a reference standard for lipid nanoparticle formulation studies. Its primary application is in the construction of biological delivery vehicles. It has been used in mRNA vaccine research but is not an approved therapeutic agent.
|
| Molecular Formula |
C42H77NO2
|
|---|---|
| Molecular Weight |
628.07
|
| Exact Mass |
627.595
|
| CAS # |
1221271-55-1
|
| PubChem CID |
58473247
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
15.7
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
35
|
| Heavy Atom Count |
45
|
| Complexity |
672
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC
|
| InChi Key |
BAHNSDYHBUZBBI-KWXKLSQISA-N
|
| InChi Code |
InChI=1S/C42H77NO2/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-41(45-42(44)39-40-43(3)4)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h13-16,19-22,41H,5-12,17-18,23-40H2,1-4H3/b15-13-,16-14-,21-19-,22-20-
|
| Chemical Name |
[(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 3-(dimethylamino)propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (159.22 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (3.98 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5922 mL | 7.9609 mL | 15.9218 mL | |
| 5 mM | 0.3184 mL | 1.5922 mL | 3.1844 mL | |
| 10 mM | 0.1592 mL | 0.7961 mL | 1.5922 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
